请选择 进入手机版 | 继续访问电脑版

搜索

The first 6 hospitals in Beijing joined The STARHB Program

2022-8-28 17:00/ 发布者: Jay/ 查看: 720/ 评论: 0

  On August 27, 2022,  The STARHB Program for clinical treatment of hepatitis B was launched in Beijing, which is the first large-scale public welfare project targeting non active HBeAg negative chronic hepatitis B infected persons (referred to as IHC population). Six medical institutions, including Beijing You'an Hospital, Beijing Ditan Hospital, the Fifth Medical Center of the PLA General Hospital, Shougang Hospital affiliated to Peking University, the First Affiliated Hospital of Tsinghua University, and the First Hospital of Fangshan District in Beijing, have joined the project as the first batch of base hospitals and sub center hospitals jointly built in Beijing.




   The STARHB Program for clinical treatment of hepatitis B was guided by Academician Zhuang Hui, a famous liver disease expert, initiated by the China Liver Health, led by Professor Chen Xinyue of Beijing You'an Hospital affiliated to Capital Medical University and Professor Gao Zhiliang of the Third Affiliated Hospital of Sun Yat sen University, and jointly carried out with national medical institutions. Xiamen Tebo provides public welfare support and drug assistance.


  The program aims to help more people with chronic hepatitis B virus infection to obtain clinical cure, help realize the "Healthy China 2030 Action", and achieve the World Health Organization's goal of "eliminating the public health hazards of viral hepatitis by 2030". At present, 38 co built base hospitals and 224 co built sub center hospitals in 28 provinces (municipalities and autonomous regions) have signed up to participate in the first batch of hospitals in China.


Professor Wei Lai of Tsinghua Changgung Hospital and Director Li Mingyang of China Liver Health awarded the plaque of  The STARHB Program co built base hospitals to Beijing You'an Hospital, Beijing Ditan Hospital and the Fifth Medical Center of the PLA General Hospital

 

Professor Wei Lai of Tsinghua Changgeng Hospital and Director Li Mingyang of China Liver Health awarded Shougang Hospital affiliated to Peking University, the First Affiliated Hospital of Tsinghua University, and the First Hospital of Fangshan District of Beijing with the plaque of  The STARHB Program co built sub center hospitals

 

Professor Wei Lai of Tsinghua Changgung Hospital and Professor Chen Xinyue of Beijing You'an Hospital awarded the appointment letter to the academic guidance experts of  The STARHB Program


Hidden progress of the disease in IHC population

The risk of liver cancer is significantly higher


  There are about 86 million chronic hepatitis B infections in China, of which 30 million are non active HBeAg negative infections (referred to as IHC population). Without intervention, chronic hepatitis B virus infection rarely heals itself, which increases the risk of progression to cirrhosis and liver cancer.


  The latest research found that although the disease progress of IHC population is slow, it is easy to be ignored by infected people, but about 50% of them have significant liver histopathological changes. According to statistics, the risk of liver cancer in Asian IHC population is 10 times higher than that in European and American populations, and the risk of liver cancer in Chinese IHC population is 4.6 times higher than that in healthy people, which needs more attention.



The immune status of IHC population is good

It is expected to achieve clinical cure


  Professor Gao Zhiliang, the leading expert of  The STARHB Program, pointed out that the serological conversion of HBeAg is usually achieved in IHC population without receiving antiviral treatment, which indicates that such patients have good immune status and are easier to achieve clinical cure; This has also been confirmed by a number of research data.


  Considering that the IHC population in China is up to 30 million, it is of great medical value and social significance to promote clinical healing practice, grasp the best treatment opportunity, optimize the healing path, and summarize and promote the healing experience.



Pegylated interferon α Treat patients with IHC

The clearance rate of HBsAg is up to 47%


  In the past 10 years, Chinese experts have been leading the world in the exploration of clinical cure of chronic hepatitis B, and many large-scale clinical practices have made remarkable achievements. The study confirmed that pegylated interferon was used α The treatment of IHC patients can obtain a higher clinical cure rate.


      The latest meta-analysis of the team of Professor Chen Xinyue, the leading expert of  The STARHB Program, found that the patients with IHC received pegylated interferon α After 48 weeks of treatment, the clearance rate of HBsAg was as high as 47%, which was significantly better than that of patients with chronic hepatitis B.

 

     Relevant studies also found that that the clearance rate of HBsAg would continue to increase after 24 weeks of follow-up after drug withdrawal, and appropriate extension of treatment would help to improve the clearance rate of HBsAg; Pegylated interferon α the clearance rate of HBsAg in patients with IHC at 96 weeks was higher than that at 48 weeks.


      However, what kind of people is more suitable for prolonged treatment is still worth further exploration.



Build a national hepatitis B clinical cure team

To help realize a healthy China

  IHC is a hepatitis B infected population that is often ignored clinically


  Professor Wei Lai, honorary chairman of the Hepatology Branch of the Chinese Medical Association and professor of Beijing Tsinghua Changgeng Hospital, said that  The STARHB Program, which brings together top experts and many grassroots hospitals in China, is conducive to cultivating young front-line teams. In the process of promoting clinical diagnosis and treatment of IHC, it makes curing chronic hepatitis B and eliminating the harm of viral hepatitis an accessible goal, and makes contributions to the health of the next generation of Chinese people.


  Li Mingyang, director of China Liver Health, said that as the world's largest sample of chronic hepatitis B infection clinical research,  The STARHB Program plans to include 15000 patients with IHC within two years, which will help accumulate large sample evidence-based data, explore and optimize the treatment path for IHC patients, bring new hope for clinical cure for IHC, a large group of chronic hepatitis B infection, and thus reduce the risk of chronic hepatitis B related cirrhosis and liver cancer, Help realize a healthy China!




相关阅读

相关分类

返回顶部